Remdesivir, is approved in India for the treatment of suspected or laboratory confirmed incidences of COVID-19 in adults and children hospitalized with severe presentations of the disease.
The COVID-19 disease is relatively new and as this drug has seen significant usage in hospitalized patients, there is a need for clinicians to share their experiences on the topic. Indian Medical Association - Tamil Nadu (IMA TNSB), welcomes doctors to an recorded informative session on "Remdesivir for treatment of COVID-19 patients".
"0.5 CME credit was awarded by TNMC"
IMA Highlights Tamil Nadu
Module 1: Clinical experience with different treatment options (Dr. Nandagopal Velayuthaswamy)
●Present situation of COVID-19 and quires to disease related addressed
●RT-PCR the Gold Standard for Diagnosis of COVID19 discussed
Case presentations with discussion on
●History and investigation
●Radiological markers explained with examples
●Recurrence of symptoms and management
●Very early phase tests may be negative
●Consider duration of illness for testing
●Don’t hesitate to repeat tests
●Always consider switching treatment medications if no clinical improvement
Module 2: Remdesivir in COVID19 - Current status and Practical Issues (Dr Ravindra Mehta)
●Proven treatment stratergies
●Anti – inflammatory therapy Steroids
●Discussion on remdesivir and positives and negatives of usage from literature review and personal experience discussed
Module 3: Clinical studies, treatment current experience & expectation from the near future (Dr M.N. Sivakumar)
●Literature review of COVID -19 and Remdesivir
●Personal experience of use of Remdisivir at RCH hospital explained
Question raised addressed in interactive session
We wish you a great learning experience and thank our sponsors Mylan Pharmaceuticals Pvt. Ltd. to make this program possible.
Thank you for showing interest in Remdesivir for treatment of COVID-19 patients. We are sorry that the course is unavailable at the moment. Please leave your contact details and we will notify you of related courses or upcoming dates.